We have shown here evidence of crosstalk between the GLI1 signaling and NFκB pathways in both EMT and claudin-low cell lines, indicating that activated GLI1, could be a mechanism that also operates in breast cancer stem cells. This evidence concerns the gene GLI1 and breast carcinoma.